Evidence map›Paper›PMID 36235226›Full record

ArticleMolecules (Basel, Switzerland)2022

Deactivatable Bisubstrate Inhibitors of Protein Kinases.

Tanel Sõrmus, Darja Lavogina, Erki Enkvist, Asko Uri, Kaido Viht

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tanel SõrmusInstitute of Chemistry, University of Tartu, 14A Ravila St., 50411 Tartu, Estonia.ORCID 0000-0001-7238-235X
Darja LavoginaInstitute of Chemistry, University of Tartu, 14A Ravila St., 50411 Tartu, Estonia.ORCID 0000-0001-5167-2817
Erki EnkvistInstitute of Chemistry, University of Tartu, 14A Ravila St., 50411 Tartu, Estonia.ORCID 0000-0001-7375-3765
Asko UriInstitute of Chemistry, University of Tartu, 14A Ravila St., 50411 Tartu, Estonia.ORCID 0000-0001-5436-2427
Kaido VihtInstitute of Chemistry, University of Tartu, 14A Ravila St., 50411 Tartu, Estonia.ORCID 0000-0002-0359-7426
University of Tartu · EE

Funding

Estonian Research Council PRG454
6 · The paper itself

Abstract

Bivalent ligands, including bisubstrate inhibitors, are conjugates of pharmacophores, which simultaneously target two binding sites of the biomolecule. Such structures offer attainable means for the development of compounds whose ability to bind to the biological target could be modulated by an external trigger. In the present work, two deactivatable bisubstrate inhibitors of basophilic protein kinases (PKs) were constructed by conjugating the pharmacophores via linkers that could be cleaved in response to external stimuli. The inhibitor ARC-2121 incorporated a photocleavable nitrodibenzofuran-comprising β-amino acid residue in the structure of the linker. The pharmacophores of the other deactivatable inhibitor ARC-2194 were conjugated via reduction-cleavable disulfide bond. The disassembly of the inhibitors was monitored by HPLC-MS. The affinity and inhibitory potency of the inhibitors toward cAMP-dependent PK (PKAcα) were established by an equilibrium competitive displacement assay and enzyme activity assay, respectively. The deactivatable inhibitors possessed remarkably high 1-2-picomolar affinity toward PKAcα. Irradiation of ARC-2121 with 365 nm UV radiation led to reaction products possessing a 30-fold reduced affinity. The chemical reduction of ARC-2194 resulted in the decrease of affinity of over four orders of magnitude. The deactivatable inhibitors of PKs are valuable tools for the temporal inhibition or capture of these pharmacologically important enzymes.

Indexed as

Protein Kinase InhibitorsProtein KinasesAmino AcidsBinding SitesDisulfidesEnzyme InhibitorsAmino AcidsDisulfidesEnzyme InhibitorsProtein Kinase InhibitorsProtein Kinasesbisubstratebivalentdeactivatable inhibitormultivalentphotocageprotein kinasestimuli-responsive

Identifiers

PMID36235226
PMCPMC9573699
OpenAlexW4303958889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.